Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06598059 · ClinicalTrials.gov registry record · NA
Safety and Efficacy of a Drug Eluting Slim Modiolar Electrode Array
A NA study of Hearing Loss, sponsored by Cochlear.
- Active
- Registry status
- NA
- Development phase
- 56
- Enrollment target
- 11
- Study locations
NCT06598059: Active NA study of Hearing Loss, sponsored by Cochlear.
NCT06598059 is a NA study of Hearing Loss that is active but no longer recruiting, run by Cochlear. The registered enrollment target is 56 participants, below the 6,120-participant average among 58 other Hearing Loss trials with a reported enrollment target (99% lower). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06598059, a NA study of Hearing Loss, is active but no longer recruiting, sponsored by Cochlear.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 56 participants
- Enrollment target
- 11
- Study locations
Study Summary
This clinical study will test a new type of cochlear implant known as CI632D. This experimental cochlear implant has been designed to slowly release a drug called dexamethasone. Dexamethasone works to ease inflammation and reduce tissue injury, which is common after any type of surgery. The goal is to learn if the dexamethasone in the CI632D implant lessens these reactions inside the ear following surgery and if this makes the implant work as well, or even better, in improving hearing than what would be expected with a standard cochlear implant. The study will be conducted in adults with sensorineural hearing loss, a type of hearing loss caused by damage to the inner ear or auditory nerve (the nerve that carries sound signals from the ear to the brain). The study participants will receive the CI632D experimental implant and will complete tests to see how well they are hearing and how well the implant is working.
Primary Outcome
Impedance will be measured across the active electrodes of the implant for each participant.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DEVICE Cochlear implant
Study Locations (11)
New York
- New York Eye and Ear Infirmary - New York
- NYU Langone Health - New York
- Northwell Health Long Island Jewish Medical Center - New York
California
- UCLA Medical Center - Los Angeles
Colorado
- Rocky Mountain Ear Center - Englewood
Iowa
- University of Iowa - Iowa City
Michigan
- Henry Ford Health - Detroit
Missouri
- Washington University - St Louis
Ohio
- University Hospitals - Cleveland
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2025-01-03 |
| Est. Completion | 2026-09 |
| Phase | NA |
What the registry record for NCT06598059 still lists
NCT06598059 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 6,120-participant average among 58 other Hearing Loss trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Hearing Loss appearing as the primary indexed condition, and to 2 interventions - of which Dexamethasone is the first listed.
NCT06598059 lists 11 locations in 9 states (New York, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT06598059 about?
NCT06598059 is a clinical study titled "Safety and Efficacy of a Drug Eluting Slim Modiolar Electrode Array". This clinical study will test a new type of cochlear implant known as CI632D. This experimental cochlear implant has been designed to slowly release a drug called dexamethasone. Dexamethasone works to ease inflammation and reduce tissue injury, which is common after any type of surgery. The goal is ...
What is the current status of trial NCT06598059?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 56 participants. The study started on 2025-01-03. Estimated completion is 2026-09.
What conditions does trial NCT06598059 study?
This clinical trial studies the following conditions: Hearing Loss.
What interventions are being tested in trial NCT06598059?
The interventions under investigation include: Dexamethasone (DRUG), Cochlear implant (DEVICE).
Who is sponsoring clinical trial NCT06598059?
This trial is sponsored by Cochlear, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06598059 being conducted?
This trial has 11 study locations across California, Colorado, Iowa, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hearing Loss
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06598059's enrollment target sits among peer trials
56 36th of 58 higher than 23 of 58 other Hearing Loss trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hearing Loss trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Access and Affordability of Adult Hearing Healthcare
RECRUITING · NA
-
AI Noise Reduction in Phonak Hearing Aids
RECRUITING · NA
-
Investigation of a Device to Deliver Intra-Operative Therapeutic Hypothermia for Hearing Preservation in Cochlear Implantation
RECRUITING · NA
-
Auditory-Cognitive Training to Optimize Outcomes for Older CI Users
RECRUITING · NA
-
Innovations in Hearing Accessibility and Technology (IHAT) Study
RECRUITING · NA
-
Clinical Utility of Residual Hearing in the Cochlear Implant Ear
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI